Sort   by:  
 Page size 
ProteomicsExpression of proteins by a marine Brevibacterium casei #NIOSBA88 in response to Arsenic and Chromium
A marine bacterial isolate, Brevibacterium casei #NIOSBA88 was grown separately in Luria Bertini broth supplemented with 750 mg L-1 Arsenic (III) and 100 mg L-1 Chromium respectively. Similarly, the strain was grown in absence of Arsenic and Chromium, which served as an experimental control. The cel...
ORGANISM(S): Brevibacterium casei 
2020-10-21 | PXD016588 | Pride
Peptide mass fingerprinting Trypsin digestion Lcms qtof 
ProteomicsResponse of marine Staphylococcus cohnii strain to Chromium
Study of expression of proteins as a response to varying chromium concentrations
ORGANISM(S): Staphylococcus cohnii 
2019-12-02 | PXD012993 | Pride
Protein Lc-ms qtof Chromium Peptide mass fingerprinting 
ProteomicsProteomic response of Staphylococcus sp. NIOSBK35 to varying arsenic (III) concentrations
Protein expression in Staphylococcus sp. NIOSBK35 isolated from marine environment (mangrove sediments) to different concentrations of arsenic (III)
ORGANISM(S): Staphylococcus cohnii 
2019-12-02 | PXD013569 | Pride
Arsenic (iii) Lc-ms qtof Marine-derived Peptide mass fingerprinting 
UnknownCellular response of Brevibacterium casei #NIOSBA88 to arsenic and chromium-a proteomic approach.
Not available
S-EPMC7688859 | biostudies-literature
TranscriptomicsTranslational profiling of hypocretin neurons identifies Lhx9 as necessary for normal development of the hypocretinergic system.
The immense molecular diversity of neurons challenges our ability to deconvolve the relationship between the genetic and the cellular underpinnings of neuropsychiatric disorders. Hypocretin (orexin) containing neurons of the lateral hypothalamus are clearly essential for the normal regulation of sle...
ORGANISM(S): Mus musculus 
2013-03-22 | E-GEOD-38668 | biostudies-arrayexpress
GenomicsThe immunopathological landscape of human pre-TCRα deficiency: from rare to common variants
The immunopathological landscape of human pre-TCRα deficiency: from rare to common variants
PRJNA1020588 | ENA
UnknownTime to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical Trial.
Not available
S-EPMC11581631 | biostudies-literature
UnknownHigher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial.
Not available
S-EPMC10656670 | biostudies-literature
UnknownAcute Cardiac Care 2012
Not available
S-EPMC3760571 | biostudies-literature
UnknownMetformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.
Not available
S-EPMC12303861 | biostudies-literature
Sort   by:  
 Page size